Romiplostim as a treatment for immune thrombocytopenia: a review

Romiplostim as a treatment for immune thrombocytopenia: a review

Sarah Chalmers,1,2 Michael D Tarantino1–31University of Illinois College of Medicine – Peoria, 2The Children's Hospital of Illinois, 3The Bleeding and Clotting Disorders Institute, Peoria, Illinois, USAAbstract: “Immune thrombocytopenia” (ITP) is an au...

Full description

Bibliographic Details
Main Authors:	Chalmers S, Tarantino MD
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-01-01
Series:	Journal of Blood Medicine
Online Access:	http://www.dovepress.com/romiplostim-as-a-treatment-for-immune-thrombocytopenia-a-review-peer-reviewed-article-JBM

Similar Items

Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency
by: Francesca Palandri, et al.
Published: (2012-06-01)

The role of romiplostim for pediatric patients with immune thrombocytopenia
by: Hanny Al-Samkari, et al.
Published: (2020-04-01)

Romiplostim for the Treatment of Immune Thrombocytopenia: Spotlight on Patient Acceptability and Ease of Use
by: Gilbert MM, et al.
Published: (2020-07-01)

Safety and efficacy of romiplostim in children and adolescents with Immune thrombocytopenia: A systematic review
by: Fernanda Lubiana de Oliveira, et al.
Published: (2023-01-01)

Romiplostim for the Emergency Management of Severe Immune Thrombocytopenia with Intracerebral Hemorrhage
by: Romain Gellens, et al.
Published: (2018-01-01)

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
by: D. J. Kuter, et al.
Published: (2015-01-01)

Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
by: D. J. Kuter, et al.
Published: (2015-01-01)

Total remission of severe immune thrombocytopenia after short term treatment with romiplostim
by: Efthymia Vlachaki, et al.
Published: (2011-10-01)

Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia
by: Hyun Ji Lim, et al.
Published: (2021-04-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Immunomodulation in Primary Immune Thrombocytopenia: A Possible Role of the Fc Fragment of Romiplostim?
by: Alexandra Schifferli, et al.
Published: (2019-06-01)

Role of thrombopoietin stimulating agents(Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE
by: Toro Vélez, Esteban, et al.
Published: (2021-07-01)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2018-01-01)

PB2612: UNITED KINGDOM RETROSPECTIVE OBSERVATIONAL STUDY OF ROMIPLOSTIM AND OTHER TREATMENTS IN EARLY IMMUNE THROMBOCYTOPENIA
by: Vickie Mcdonald, et al.
Published: (2023-08-01)

Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
by: Tremblay G, et al.
Published: (2018-11-01)

Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim
by: Christian Fynbo Christiansen, et al.
Published: (2019-09-01)

Romiplostim for chemotherapy‐induced thrombocytopenia: Efficacy and safety of extended use
by: Cy R. Wilkins, et al.
Published: (2022-03-01)

Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignancies
by: Abraham Z. Cheloff, et al.
Published: (2022-11-01)

Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description
by: Rodriguez Nuñez Rosa María, et al.
Published: (2020-04-01)

Romiplostim-associated increase in CD34+ megakaryocytes in a case of immune thrombocytopenia: A case report
by: Charles M. Lombard, et al.
Published: (2023-06-01)

Missing Cells - A Rare Case of Persisting Thrombocytopenia in Pregnancy With Dengue and Role of Romiplostim in These Cases
by: Ruchita Sinha, et al.
Published: (2023-06-01)

Short-term dose-escalated romiplostim for preparing an adult patient with persistent newly diagnosed primary immune thrombocytopenia for splenectomy
by: Nigel P. Murray, et al.
Published: (2020-07-01)

Rapid response to mycophenolate mofetil in combination with romiplostim in a case of severe refractory immune thrombocytopenia post COVID‐19 vaccination
by: Snigdha Nutalapati, et al.
Published: (2021-11-01)

PB2308: QUALITY OF LIFE AND CLINICAL OUTCOMES IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (CITP) DURING TREATMENT WITH ROMIPLOSTIM IN A REAL-WORLD SETTING
by: T. Ionova, et al.
Published: (2022-06-01)

THE USE OF ROMIPLOSTIM IN AN INFANT
by: Fatma Burçin KURTİPEK, et al.
Published: (2021-11-01)

Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01)

Clinical experience with romiplostim
by: G. B. Kuchma, et al.
Published: (2014-07-01)

Romiplostim – an emergency treatment of intracranial haemorrhage in the course of severe primary immune thrombocytopaenia
by: Paweł Łaguna, et al.
Published: (2022-12-01)

Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal
by: G Mowatt, et al.
Published: (2009-09-01)

PB2307: A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ROMIPLOSTIM PLUS DEXAMETHASONE VS DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED PRIMARY IMMUNE THROMBOCYTOPENIA
by: M. E. Mingot Castellano, et al.
Published: (2022-06-01)

SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR
by: A. N. Afanasyeva, et al.
Published: (2022-10-01)

PB2622: A PROSPECTIVE, OPEN-LABEL ONGOING STUDY OF SAFETY AND TREATMENT SATISFACTION IN ADULT IMMUNE THROMBOCYTOPENIA (ITP) SUBJECTS AFTER SWITCHING TO AVATROMBOPAG FROM ELTROMBOPAG OR ROMIPLOSTIM
by: Scott Kolodny, et al.
Published: (2023-08-01)

Therapeutic Outcomes of High Dose-Dexamethasone versus Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim Strategies in Persistent, Chronic, Refractory, and Relapsed Immune Thrombocytopenia Patients
by: Eman Mostafa Hamed, et al.
Published: (2023-08-01)

Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice
by: Monica Carpenedo, et al.
Published: (2015-02-01)

Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar
by: Abdulrahman F. Al-Mashdali, et al.
Published: (2023-12-01)

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
by: Igor Makarenko, et al.
Published: (2023-10-01)

Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim
by: Muhammad Awidi, et al.
Published: (2021-02-01)

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
by: Fanqiao Meng, et al.
Published: (2020-11-01)

Developmental differences between newborn and adult mice in response to romiplostim
by: Katherine A. Sparger, et al.
Published: (2018-05-01)